T.H. Chan School of Medicine Student Publications
Title
Topical 5% 5-fluorouracil versus procedural modalities for squamous cell carcinoma in situ and superficial basal cell carcinoma: A retrospective cohort analysis
UMMS Affiliation
Department of Dermatology; Department of Population and Quantitative Health Sciences; School of Medicine
Publication Date
2021-08-31
Document Type
Article
Disciplines
Dermatology | Skin and Connective Tissue Diseases
Abstract
The topical chemotherapeutic agent 5-fluorouracil (5-FU) is commonly used to treat squamous cell carcinoma in situ (SCCIS) and superficial basal cell carcinoma (sBCC). Additional investigation is needed to understand whether topical 5-FU, under real-world conditions, has comparable treatment success to procedures for epidermally-limited keratinocyte carcinomas. Approval was obtained from the University of Massachusetts Medical School institutional review board to perform a retrospective chart review.
Keywords
carcinomas, 5-fluorouracil
DOI of Published Version
10.1016/j.jaad.2021.08.045
Source
Neale H, Michelon M, Jacob S, Pinkston M, Ukaegbu R, Zamor W, Morrison E, Deng A, Levin NA. Topical 5% 5-fluorouracil versus procedural modalities for squamous cell carcinoma in situ and superficial basal cell carcinoma: A retrospective cohort analysis. J Am Acad Dermatol. 2021 Aug 31:S0190-9622(21)02390-2. doi: 10.1016/j.jaad.2021.08.045. Epub ahead of print. PMID: 34478783.
Journal/Book/Conference Title
Journal of the American Academy of Dermatology
Related Resources
PubMed ID
34478783
Repository Citation
Neale H, Michelon M, Jacob S, Pinkston M, Ukaegbu R, Zamor W, Morrison E, Deng A, Levin NA. (2021). Topical 5% 5-fluorouracil versus procedural modalities for squamous cell carcinoma in situ and superficial basal cell carcinoma: A retrospective cohort analysis. T.H. Chan School of Medicine Student Publications. https://doi.org/10.1016/j.jaad.2021.08.045. Retrieved from https://escholarship.umassmed.edu/som_pubs/14